44 completed, 10 terminated, 5 recruiting, 4 unknown. 69 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 69 | Completed 44, Terminated 10, Recruiting 5, Unknown 4, Withdrawn 4, Suspended 2 |
| Phase 2 | 22 | Completed 13, Unknown 3, Recruiting 2, Terminated 2, Suspended 1, Withdrawn 1 |
Follow Hyperglycemia: new trials by email Literature Review of Hyperglycemia trials Research Report on Hyperglycemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study Egg White Powder - High Blood Sugar, High Blood Pressure | Phase 1 | Recruiting | University of Alberta | 28 | 2026-02-25 | 2026-10-26 |
| Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes Arginine hydrochloride, Sodium Chloride 0.9% - Diabetes (DM), Diabetic Ketoacidosis | Phase 1 / Phase 2 | Recruiting | David K Carroll | 60 | 2025-12-19 | 2026-02-12 |
| A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects TQF3250 placebo, TQF3250 capsule - Hyperglycemia | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 66 | 2025-12-18 | 2026-01-08 |
| Prevention of Progression of Prediabetes, Obesity and CV Risk Placebo, Rybelsus Tablet, Jardiance 25Mg Tablet - Pre-Diabetes, Weight, Body | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 64 | 2024-09-11 | 2025-11-12 |
| Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus HM-002-1005 - Diabetes Mellitus, Type II | Phase 1 | Completed | Hua Medicine Limited | 40 | 2024-04-25 | 2025-04-03 |
| Oral Peri-operative TIming of Metformin (or) Salsalate to Improve Non-cardiac Surgery Glucose Control Metformin, Salsalate - Diabetes Mellitus, Type 2, Hyperglycemia | Phase 1 | Withdrawn | McMaster University | 2023-12-01 | 2026-06-12 | |
| Expanding Use of CGM in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes Dexcom G6 - Hyperglycemia | Phase 1 / Phase 2 | Completed | Ohio State University | 201 | 2023-11-01 | 2026-02-06 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 AZD0186, Placebo - Type 2 Diabetes | Phase 1 | Terminated | AstraZeneca | 31 | 2022-12-20 | 2024-12-13 |
| Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D AT-1501 IV Infusion, Isolated cadaveric islet cells - Brittle Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Withdrawn | Eledon Pharmaceuticals | 2022-09-30 | 2023-01-18 | |
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer Evexomostat - HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | SynDevRx, Inc. | 52 | 2022-08-26 | 2026-04-22 |
| Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT Dorzagliatin, Placebo - Glucose Intolerance | Phase 1 / Phase 2 | Unknown | Chinese University of Hong Kong | 20 | 2022-08-01 | 2022-07-25 |
| SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot Empagliflozin 25 MG - Obesity, Pre-diabetes | Phase 1 / Phase 2 | Completed | Vanderbilt University Medical Center | 29 | 2021-07-29 | 2023-12-29 |
| Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477) REMD-477 - Hyperglycemia Drug Induced | Phase 1 | Terminated | Duke University | 1 | 2020-11-13 | 2022-11-08 |
| Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons Calcitriol capsules, Oral Placebo - Pre-Diabetic | Phase 1 | Terminated | Mayo Clinic | 17 | 2020-10-01 | 2022-04-18 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Relacorilant, Pembrolizumab - Adrenocortical Carcinoma | Phase 1 | Completed | Corcept Therapeutics | 15 | 2020-09-30 | 2024-02-23 |
| Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke Pioglitazone 45 mg, Placebo oral tablet - Stroke, Acute, Hyperglycemia | Phase 1 / Phase 2 | Terminated | Milton S. Hershey Medical Center | 1 | 2020-09-01 | 2022-09-15 |
| SGLT2 Inhibition in Older Obese Adults With Pre-diabetes Dapagliflozin 10 mg, Nutritional counseling - Aging | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 20 | 2020-06-25 | 2024-01-05 |
| A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib REMD-477 - Hyperglycemia Drug Induced | Phase 1 | Terminated | Duke University | 1 | 2020-04-07 | 2021-06-11 |
| Magnesium Replacement and Hyperglycemia After Kidney Transplantation Mablet 360 mg, Placebo - Hypomagnesemia, Kidney Transplantation | Phase 1 / Phase 2 | Unknown | Oslo University Hospital | 40 | 2020-02-25 | 2021-09-28 |
| Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes Insulin - Type 1 Diabetes, Hyperglycemia, Postprandial | Phase 1 / Phase 2 | Terminated | Washington University School of Medicine | 1 | 2020-02-13 | 2022-10-07 |
Showing 20 of 69. Sign in to see all of them.
Glucose Intolerance (27) · Diabetes Mellitus (17) · Diabetes Mellitus, Type 2 (10) · Hypoglycemia (10) · Insulin Resistance (8) · Diabetes Mellitus, Type 1 (7) · Obesity (5) · Prediabetic State (5) · Endocrine System Diseases (3) · Hypertension (3) · Metabolic Syndrome (3) · Breast Neoplasms (2) · Cardiovascular Diseases (2) · Cushing Syndrome (2)
Glucose Metabolism Disorders (69) · Nutritional and Metabolic Diseases (69) · Metabolic Diseases (68) · Endocrine System Diseases (28) · Pathological Conditions, Signs and Symptoms (15) · Diabetes Mellitus (14) · Hyperinsulinism (9) · Signs and Symptoms (9) · Cardiovascular Diseases (8) · Immune System Diseases (8) · Body Weight (7) · Vascular Diseases (7) · Autoimmune Diseases (6) · Nutrition Disorders (6)
Insulin (4) · Metformin (4) · Exenatide (3) · Islets of Langerhans Transplantation (3) · Pioglitazone (3) · Sodium Chloride (3) · Catechin (2) · Glucagon-Like Peptide 1 (2) · Saline Solution (2) · empagliflozin (2) · volagidemab (2) · AZD1656 (1) · Albumins (1) · Arginine (1) · Atropine (1)
Baylor Research Institute (3) · Vanderbilt University Medical Center (3) · AstraZeneca (2) · Bows Pharmaceuticals AG (2) · Duke University (2) · M.V. Hospital for Diabetes (2) · The University of Texas Health Science Center at San Antonio (2) · Veterans Medical Research Foundation (2) · Washington University School of Medicine (2) · Yabao Pharmaceutical Group (2) · Adistem Ltd (1) · Afexa Life Sciences Inc (1) · Albert Einstein College of Medicine (1) · B & Y Technologies (1) · Beth Israel Deaconess Medical Center (1)
United States (43) · Canada (4) · China (4) · Sweden (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Cameroon (1) · Denmark (1) · Germany (1) · India (1) · Norway (1) · Philippines (1)
Lei Yang (2) · Nabil Al-Tawil, M.D.; Ph.D. (2) · Robert R Henry, MD (2) · Albert Frauman, MD (1) · Alexander N Prezioso, MD (1) · Ambady Ramachandran, MD,PhD,DSc (1) · Ambady Ramachandran, MD,PhD,DSc. (1) · Anastassios G Pittas, MD MS (1) · Andreas G Moraitis, MD (1) · Benjamin A. Kohl, MD (1) · Bill Paspaliaris, PhD (1) · Burton M Wice, PhD (1) · Carolina Solis-Herrera (1) · Carolina Solis-Herrera, MD (1)
PMID 11794168, PMID 19142552, PMID 19277602, PMID 20833991, PMID 21715514, PMID 27194308, PMID 27207552, PMID 28945992, PMID 30629889, PMID 31213865, PMID 32416251, PMID 33125674, PMID 33210751, PMID 33507248, PMID 33831213, PMID 35016012, PMID 35093240, PMID 35596784, PMID 39513382, PMID 42746746, PMID 8550855, PMID 9033300, PMID 9525985
R01AT008310 (2), K23GM117395 (1), P30AG044271 (1), R01DK076092 (1), R21DK081877 (1), ZIADK075121 (1)